Schwam E - Search Results

1

Pharmacokinetics, safety, and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers.

Zhao Q, Schwam E, Fullerton T, O'Gorman M, Burstein AH. Zhao Q, et al. Among authors: schwam e. J Clin Pharmacol. 2011 Apr;51(4):492-501. doi: 10.1177/0091270010370461. Epub 2010 May 13. J Clin Pharmacol. 2011. PMID: 20466870 Clinical Trial.

2

Phase II crossover trial of varenicline in mild-to-moderate Alzheimer's disease.

Kim SY, Choi SH, Rollema H, Schwam EM, McRae T, Dubrava S, Jacobsen J. Kim SY, et al. Among authors: schwam em. Dement Geriatr Cogn Disord. 2014;37(3-4):232-45. doi: 10.1159/000355373. Epub 2013 Nov 14. Dement Geriatr Cogn Disord. 2014. PMID: 24247022 Clinical Trial.

3

A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease.

Schwam EM, Nicholas T, Chew R, Billing CB, Davidson W, Ambrose D, Altstiel LD. Schwam EM, et al. Curr Alzheimer Res. 2014;11(5):413-21. doi: 10.2174/1567205011666140505100858. Curr Alzheimer Res. 2014. PMID: 24801218 Clinical Trial.

4

Flumazenil: US clinical pharmacology studies.

Dunton AW, Schwam E, Pitman V, McGrath J, Hendler J, Siegel J. Dunton AW, et al. Among authors: schwam e. Eur J Anaesthesiol Suppl. 1988;2:81-95. Eur J Anaesthesiol Suppl. 1988. PMID: 2842144 Review.

5

Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease.

Schwam E, Xu Y. Schwam E, et al. Dement Geriatr Cogn Disord. 2010;29(4):309-16. doi: 10.1159/000269837. Epub 2010 Apr 16. Dement Geriatr Cogn Disord. 2010. PMID: 20395684 Clinical Trial.

6

The relationship between dose and duration of action of intravenous flumazenil in reversing sedation induced by a continuous infusion of midazolam.

Dunton AW, Schwam E, Pitman V, Leese P, Siegel J. Dunton AW, et al. Among authors: schwam e. Eur J Anaesthesiol Suppl. 1988;2:97-102. Eur J Anaesthesiol Suppl. 1988. PMID: 2842145 Clinical Trial. No abstract available.

7

Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil.

Jones RW, Schwam E, Wilkinson D, Waldemar G, Feldman HH, Zhang R, Albert K, Schindler R. Jones RW, et al. Among authors: schwam e. Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):357-64. doi: 10.1097/WAD.0b013e31819cd4be. Alzheimer Dis Assoc Disord. 2009. PMID: 19561444

8

Health economics and the value of therapy in Alzheimer's disease.

Schwam EM, Abu-Shakra S, del Valle M, Townsend RJ, Carrillo MC, Fillit H. Schwam EM, et al. Alzheimers Dement. 2007 Jul;3(3):143-51. doi: 10.1016/j.jalz.2007.04.391. Alzheimers Dement. 2007. PMID: 19595929

9

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group. Feldman H, et al. Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69. doi: 10.1002/gps.1325. Int J Geriatr Psychiatry. 2005. PMID: 15920715 Clinical Trial.

10

Predicting cognitive decline in Alzheimer's disease: an integrated analysis.

Lopez OL, Schwam E, Cummings J, Gauthier S, Jones R, Wilkinson D, Waldemar G, Zhang R, Schindler R. Lopez OL, et al. Among authors: schwam e. Alzheimers Dement. 2010 Nov;6(6):431-9. doi: 10.1016/j.jalz.2010.04.003. Alzheimers Dement. 2010. PMID: 21044773 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41 results

Search Page

Filters